Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Regeneron Pharmaceuticals Inc (NASDAQ:REGN)

404.12
Delayed Data
As of 3:59pm ET
 -6.27 / -1.53%
Today’s Change
329.09
Today|||52-Week Range
592.59
-25.56%
Year-to-Date
Regeneron, Sanofi Skin Disease Drug Under Priority Review
4:32pm / Zacks.com - Paid Partner Content
Regeneron, Teva Collaborate to Develop Chronic Pain Drug
Sep 21 / Zacks.com - Paid Partner Content
3 Growth Stocks You Can Buy Cheap Right Now
1:08pm / MotleyFool.com - Paid Partner Content
Biotech Stock Roundup: Tobira Soars on Acquisition Deal, FDA Says Yes to Sarepta DMD ...
Sep 21 / Zacks.com - Paid Partner Content
5 Stocks with Impressive Sales Growth to Bet On
11:09am / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close410.39
Today’s open410.00
Day’s range401.10 - 410.00
Volume658,631
Average volume (3 months)824,670
Market cap$43.2B
Dividend yield--
Data as of 3:59pm ET, 09/26/2016

Growth & Valuation

Earnings growth (last year)+79.80%
Earnings growth (this year)-8.87%
Earnings growth (next 5 years)+18.00%
Revenue growth (last year)+45.55%
P/E ratio63.0
Price/Sales15.24
Price/Book11.75

Competitors

 Today’s
change
Today’s
% change
ALXNAlexion Pharmaceutic...-2.71-2.13%
BAXBaxter International...-0.29-0.61%
ZTSZoetis Inc-0.30-0.58%
SHPGShire-3.96-1.95%
Data as of 4:02pm ET, 09/26/2016

Financials

Next reporting dateNovember 1, 2016
EPS forecast (this quarter)$2.72
Annual revenue (last year)$4.1B
Annual profit (last year)$636.1M
Net profit margin15.50%

Profile

Sector
Health Technology
Industry
Biotechnology
President, CEO &
Class I Director
Leonard S. Schleifer
Chief Financial Officer &
Senior VP-Finance
Robert E. Landry
Corporate headquarters
Tarrytown, New York

Forecasts

Search for Jobs